<?xml version='1.0' encoding='utf-8'?>
<document id="30981875"><sentence text="Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use." /><sentence text="In recent years, experimental research on lysergic acid diethylamide (LSD) in humans has gained new momentum"><entity charOffset="42-68" id="DDI-PubMed.30981875.s2.e0" text="lysergic acid diethylamide" /><entity charOffset="70-73" id="DDI-PubMed.30981875.s2.e1" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s2.e0" e2="DDI-PubMed.30981875.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s2.e0" e2="DDI-PubMed.30981875.s2.e1" /></sentence><sentence text=" In humans, LSD is metabolized rapidly into several metabolites but knowledge of the involved metabolizing enzymes is limited"><entity charOffset="12-14" id="DDI-PubMed.30981875.s3.e0" text="LSD" /></sentence><sentence text=" The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) in vitro, in order to evaluate potential effects of enzyme polymorphisms or prescription drugs on LSD pharmacokinetics"><entity charOffset="164-183" id="DDI-PubMed.30981875.s4.e0" text="2-oxo-3-hydroxy-LSD" /><entity charOffset="111-129" id="DDI-PubMed.30981875.s4.e1" text="LSD" /><entity charOffset="155-173" id="DDI-PubMed.30981875.s4.e2" text="LSD" /><entity charOffset="180-198" id="DDI-PubMed.30981875.s4.e3" text="LSD" /><entity charOffset="189-207" id="DDI-PubMed.30981875.s4.e4" text="LSD" /><entity charOffset="292-310" id="DDI-PubMed.30981875.s4.e5" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e1" e2="DDI-PubMed.30981875.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e2" e2="DDI-PubMed.30981875.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e2" e2="DDI-PubMed.30981875.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e2" e2="DDI-PubMed.30981875.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e2" e2="DDI-PubMed.30981875.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e2" e2="DDI-PubMed.30981875.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e0" e2="DDI-PubMed.30981875.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e0" e2="DDI-PubMed.30981875.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e0" e2="DDI-PubMed.30981875.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e0" e2="DDI-PubMed.30981875.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e3" e2="DDI-PubMed.30981875.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e3" e2="DDI-PubMed.30981875.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e3" e2="DDI-PubMed.30981875.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e4" e2="DDI-PubMed.30981875.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s4.e4" e2="DDI-PubMed.30981875.s4.e5" /></sentence><sentence text=" Additionally, interactions of LSD and both metabolites with 5-hydroxytryptamine (5-HT) receptors were assessed"><entity charOffset="61-80" id="DDI-PubMed.30981875.s5.e0" text="5-hydroxytryptamine" /><entity charOffset="82-86" id="DDI-PubMed.30981875.s5.e1" text="5-HT" /><entity charOffset="31-34" id="DDI-PubMed.30981875.s5.e2" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s5.e2" e2="DDI-PubMed.30981875.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s5.e2" e2="DDI-PubMed.30981875.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s5.e2" e2="DDI-PubMed.30981875.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s5.e0" e2="DDI-PubMed.30981875.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s5.e0" e2="DDI-PubMed.30981875.s5.e1" /></sentence><sentence text=" LSD was incubated with human liver microsomes over 4 h and the production of nor-LSD and O-H-LSD was quantified by liquid chromatography tandem mass spectrometry"><entity charOffset="1-3" id="DDI-PubMed.30981875.s6.e0" text="LSD" /><entity charOffset="82-84" id="DDI-PubMed.30981875.s6.e1" text="LSD" /><entity charOffset="94-96" id="DDI-PubMed.30981875.s6.e2" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s6.e0" e2="DDI-PubMed.30981875.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s6.e0" e2="DDI-PubMed.30981875.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s6.e0" e2="DDI-PubMed.30981875.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s6.e1" e2="DDI-PubMed.30981875.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s6.e1" e2="DDI-PubMed.30981875.s6.e2" /></sentence><sentence text=" Metabolism was inhibited by the addition of specific CYP inhibitors" /><sentence text=" Additionally, recombinant CYPs were used to verify the inhibition results obtained with microsomes and induction of metabolism was investigated in human hepatocyte-derived cells" /><sentence text=" Radioligand binding and calcium mobilization assays were used to determine 5-HT receptor affinities and activities, respectively"><entity charOffset="25-32" id="DDI-PubMed.30981875.s9.e0" text="calcium" /><entity charOffset="76-82" id="DDI-PubMed.30981875.s9.e1" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.30981875.s9.e0" e2="DDI-PubMed.30981875.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s9.e0" e2="DDI-PubMed.30981875.s9.e1" /></sentence><sentence text=" Human liver microsomes displayed minor metabolite formation (&lt;1% metabolized) over 4 h" /><sentence text=" CYP2D6, 2E1, and 3A4 significantly contributed to the formation of nor-LSD, and CYP1A2, 2C9, 2E1, and 3A4 were significantly involved in the formation of O-H-LSD"><entity charOffset="72-75" id="DDI-PubMed.30981875.s11.e0" text="LSD" /><entity charOffset="159-162" id="DDI-PubMed.30981875.s11.e1" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s11.e0" e2="DDI-PubMed.30981875.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s11.e0" e2="DDI-PubMed.30981875.s11.e1" /></sentence><sentence text=" These findings could be verified using recombinant CYPs" /><sentence text=" Enzyme induction with rifampicin distinctly increased the formation of both metabolites, whereas treatment with omeprazole only slightly increased formation of nor-LSD"><entity charOffset="23-33" id="DDI-PubMed.30981875.s13.e0" text="rifampicin" /><entity charOffset="113-123" id="DDI-PubMed.30981875.s13.e1" text="omeprazole" /><entity charOffset="165-174" id="DDI-PubMed.30981875.s13.e2" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s13.e0" e2="DDI-PubMed.30981875.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s13.e0" e2="DDI-PubMed.30981875.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s13.e0" e2="DDI-PubMed.30981875.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s13.e1" e2="DDI-PubMed.30981875.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s13.e1" e2="DDI-PubMed.30981875.s13.e2" /></sentence><sentence text=" LSD and nor-LSD were pharmacologically active at the 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors"><entity charOffset="1-3" id="DDI-PubMed.30981875.s14.e0" text="LSD" /><entity charOffset="13-15" id="DDI-PubMed.30981875.s14.e1" text="LSD" /><entity charOffset="54-56" id="DDI-PubMed.30981875.s14.e2" text="5-HT" /><entity charOffset="62-64" id="DDI-PubMed.30981875.s14.e3" text="5-HT" /><entity charOffset="70-72" id="DDI-PubMed.30981875.s14.e4" text="5-HT" /><entity charOffset="82-84" id="DDI-PubMed.30981875.s14.e5" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e0" e2="DDI-PubMed.30981875.s14.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e1" e2="DDI-PubMed.30981875.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e1" e2="DDI-PubMed.30981875.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e1" e2="DDI-PubMed.30981875.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e1" e2="DDI-PubMed.30981875.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e1" e2="DDI-PubMed.30981875.s14.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e2" e2="DDI-PubMed.30981875.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e2" e2="DDI-PubMed.30981875.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e2" e2="DDI-PubMed.30981875.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e2" e2="DDI-PubMed.30981875.s14.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e3" e2="DDI-PubMed.30981875.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e3" e2="DDI-PubMed.30981875.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e3" e2="DDI-PubMed.30981875.s14.e5" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e4" e2="DDI-PubMed.30981875.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30981875.s14.e4" e2="DDI-PubMed.30981875.s14.e5" /></sentence><sentence text=" Nor-LSD mainly differed from the parent compound by having a lower affinity to the 5-HT2C receptor"><entity charOffset="5-8" id="DDI-PubMed.30981875.s15.e0" text="LSD" /><entity charOffset="84-87" id="DDI-PubMed.30981875.s15.e1" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.30981875.s15.e0" e2="DDI-PubMed.30981875.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s15.e0" e2="DDI-PubMed.30981875.s15.e1" /></sentence><sentence text=" O-H-LSD displayed substantially weaker affinity and activity at serotonergic receptors in comparison to LSD"><entity charOffset="5-8" id="DDI-PubMed.30981875.s16.e0" text="LSD" /><entity charOffset="105-108" id="DDI-PubMed.30981875.s16.e1" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s16.e0" e2="DDI-PubMed.30981875.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s16.e0" e2="DDI-PubMed.30981875.s16.e1" /></sentence><sentence text=" To conclude, human liver microsomes converted only small amounts of LSD to nor-LSD and O-H-LSD but several CYPs significantly contributed"><entity charOffset="69-71" id="DDI-PubMed.30981875.s17.e0" text="LSD" /><entity charOffset="80-82" id="DDI-PubMed.30981875.s17.e1" text="LSD" /><entity charOffset="92-94" id="DDI-PubMed.30981875.s17.e2" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s17.e0" e2="DDI-PubMed.30981875.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s17.e0" e2="DDI-PubMed.30981875.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s17.e0" e2="DDI-PubMed.30981875.s17.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s17.e1" e2="DDI-PubMed.30981875.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s17.e1" e2="DDI-PubMed.30981875.s17.e2" /></sentence><sentence text=" Genetic polymorphisms and drug interactions could therefore influence pharmacokinetics and pharmacodynamics of LSD"><entity charOffset="112-114" id="DDI-PubMed.30981875.s18.e0" text="LSD" /></sentence><sentence text=" Nor-LSD likely has hallucinogenic activity similar to LSD, whereas O-H-LSD is inactive"><entity charOffset="5-7" id="DDI-PubMed.30981875.s19.e0" text="LSD" /><entity charOffset="55-57" id="DDI-PubMed.30981875.s19.e1" text="LSD" /><entity charOffset="72-74" id="DDI-PubMed.30981875.s19.e2" text="LSD" /><pair ddi="false" e1="DDI-PubMed.30981875.s19.e0" e2="DDI-PubMed.30981875.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30981875.s19.e0" e2="DDI-PubMed.30981875.s19.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s19.e0" e2="DDI-PubMed.30981875.s19.e2" /><pair ddi="false" e1="DDI-PubMed.30981875.s19.e1" e2="DDI-PubMed.30981875.s19.e1" /><pair ddi="false" e1="DDI-PubMed.30981875.s19.e1" e2="DDI-PubMed.30981875.s19.e2" /></sentence><sentence text=" Drug-drug interaction studies in humans are required to further assess the clinical relevance of these findings" /><sentence text="" /></document>